Immunology and Bi...
Follow
Find
7.9K views | +1 today
 
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

New Antibody Insecticide Targets Malaria Mosquito - Science 2.0

New Antibody Insecticide Targets Malaria Mosquito - Science 2.0 | Immunology and Biotherapies | Scoop.it
New Antibody Insecticide Targets Malaria Mosquito Science 2.0 Identifying a glutamate gated chloride channel (the mosquito glutamate gated chloride channel - AgGluCl), which is an essential component of the insect's nervous system, to be the target...
Gilbert Faure au nom de l'ASSIM's insight:

antibody insecticide for mosquitoes

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Pembrolizumab shows real promise against head & neck cancer - EurekAlert (press release)

Pembrolizumab shows real promise against head & neck cancer - EurekAlert (press release) | Immunology and Biotherapies | Scoop.it
Immunotherapy with the anti-PD-1 antibody pembrolizumab decreased the size of tumors by 30 percent or more in 24.8 percent of 132 patients with recurrent or metastatic head and neck cancer.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Immunogenicity of infectious pathogens and vaccine antigens

The concept of the immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide...
Gilbert Faure au nom de l'ASSIM's insight:

The concept of the immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. However, the theoretical notion of immunogenicity as discussed in older textbooks of immunology needs reconsideration due to advances in our understanding of immunologic responses. Immunogenicity is a property that can either be a desirable attribute, for example in the generation of an effective protective immunity against infectious pathogens or an undesirable trait, for example when it relates to novel therapeutic compounds and drugs, where an immune response needs to be prevented or inhibited. In this Forum Article, we aimed to revisit the issue of immunogenicity to discuss a series of simple questions relevant to the concept that are frequently rephrased but incompletely resolved in the immunologic literature.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Visterra Announces Partnership to Develop a Monoclonal Antibody | Pharmaceutical Technology

Visterra Announces Partnership to Develop a Monoclonal Antibody | Pharmaceutical Technology | Immunology and Biotherapies | Scoop.it
Visterra announces partnership with A*STAR to develop VIS513, a monoclonal antibody for the treatment of dengue fever.
Gilbert Faure au nom de l'ASSIM's insight:

Visterra announced on May 21, 2015 that it would partner with the Drug Discovery & Development (D3) unit under the Agency for Science, Technology, and Research (A*STAR) to develop VIS51, Visterra’s neutralizing antibody meant to treat dengue fever. VIS513 is engineered using a humanized monoclonal antibody designed to neutralize all four serotypes of dengue virus, DEN-1, DEN-2, DEN-3, and DEN-4.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Development and characterization of broadly cross-reactive monoclonal antibodies against all known Ebolavirus species

Development and characterization of broadly cross-reactive monoclonal antibodies against all known Ebolavirus species | Immunology and Biotherapies | Scoop.it
Infectious Disease Article: Development and characterization of broadly cross-reactive monoclonal antibodies against all known Ebolavirus species
Gilbert Faure au nom de l'ASSIM's insight:

The Journal of Infectious Diseases, 05/26/2015Hernandez H, et al.

In the current study, a panel of experimental model monoclonal antibodies was isolated and characterized using an enzyme–linked immunosorbent assay (ELISA) to determine cross–reactivity, avidity, and competition for epitope binding; Western blot analysis was also performed. The data will be crucial for the development of novel therapeutics and diagnostic assays.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from PARP Inhibitors Cancer Review
Scoop.it!

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma - Cancer Letters

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma - Cancer Letters | Immunology and Biotherapies | Scoop.it

Highlights

 

First time demonstrating that CD47 blockade has anti-tumor effects against HCC.

In vitro CD47 blockade results in increase in phagocytosis of HCC cells.

In vivo CD47 blockade inhibits HCC tumor growth in hetero/orthotopic models.

CD47mAb400 is clearly more efficacious than widely-investigated B6H12 antibody.

 

Abstract

Human hepatocellular carcinoma (HCC) has a high rate of tumor recurrence and metastasis, resulting in shortened survival times. The efficacy of current systemic therapies for HCC is limited. In this study, we used xenograft tumor models to investigate the use of antibodies that block CD47 and inhibit HCC tumor growth. Immunostaining of tumor tissue and HCC cell lines demonstrated CD47 over-expression in HCC as compared to normal hepatocytes. Macrophage phagocytosis of HCC cells was increased after treatment with CD47 antibodies (CD47mAbs) that block CD47 binding to SIRPα. Further, CD47 blockade inhibited tumor growth in both heterotopic and orthotopic models of HCC, and promoted the migration of macrophages into the tumor mass. Our results demonstrate that targeting CD47 by specific antibodies has potential immunotherapeutic efficacy in human HCC.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 26, 1:45 AM

Cancer Letters

Volume 360, Issue 2, 1 May 2015, Pages 302–309

Original Articles Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinomaZhenyu Xiaoa, 1, Haniee Chunga, 1, Babak Banana, Pamela T. Manningb, Katherine C. Otta, Shin Linc,Benjamin J. Capocciaa, Vijay Subramaniana, Ronald R. Hiebschb, Gundumi A. Upadhyaa, Thalachallour Mohanakumara, e, William A. Frazierd, Yiing Lina, , , William C. Chapmana, ,    doi:10.1016/j.canlet.2015.02.036

Krishan Maggon 's curator insight, May 26, 1:48 AM
Cancer Letters

Volume 360, Issue 2, 1 May 2015, Pages 302–309

Original Articles Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinomaZhenyu Xiaoa, 1, Haniee Chunga, 1, Babak Banana, Pamela T. Manningb, Katherine C. Otta, Shin Linc,Benjamin J. Capocciaa, Vijay Subramaniana, Ronald R. Hiebschb, Gundumi A. Upadhyaa, Thalachallour Mohanakumara, e, William A. Frazierd, Yiing Lina, , , William C. Chapmana, ,    doi:10.1016/j.canlet.2015.02.036
Scooped by Gilbert Faure au nom de l'ASSIM from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

European Medicines Agency - News and Events - Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2015

European Medicines Agency - News and Events - Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2015 | Immunology and Biotherapies | Scoop.it
European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 22, 8:53 AM

Two generic medicines received positive opinions from the CHMP: Bortezomib Accord(bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma andPregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised anxiety disorder.

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability - Online First - Springer

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability - Online First - Springer | Immunology and Biotherapies | Scoop.it
Abstract

The convergence of advanced understanding of biology with chemistry has led to a resurgence in the development of antibody-drug conjugates (ADCs), especially with two recent product approvals. Design and development of ADCs requires the synergistic combination of the monoclonal antibody, the linker and the payload. Advances in antibody science has enabled identification and generation of high affinity, highly selective, humanized or human antibodies for a given target. Novel linker technologies have been synthesized and highly potent cytotoxic drug payloads have been created. As the first generation of ADCs utilizing lysine and cysteine chemistries moves through the clinic and into commercialization, second generation ADCs involving site specific conjugation technologies are being evaluated and tested. The latter aim to be better characterized and controlled, with wider therapeutic indices as well as improved pharmacokinetic-pharmacodynamic (PK-PD) profiles. ADCs offer some interesting physicochemical properties, due to conjugation itself, and to the (often) hydrophobic payloads that must be considered during their CMC development. New analytical methodologies are required for the ADCs, supplementing those used for the antibody itself. Regulatory filings will be a combination of small molecule and biologics. The regulators have put forth some broad principles but this landscape is still evolving.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 24, 1:57 AM
Pharmaceutical ResearchMay 2015Date: 19 May 2015Antibody-Drug Conjugates: Design, Formulation and Physicochemical StabilitySatish K. Singh, Donna L. Luisi, Roger H. Pak
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Monoclonal antibodies in acute lymphoblastic leukemia

Abstract

With modern intensive combination polychemotherapy, the complete response (CR) rate in adults with acute lymphoblastic leukemia (ALL) is 80-90%, and the cure rate 40-50%. Hence there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy. ALL leukemic cells express several surface antigens amenable to target therapies, including CD20, CD22, and CD19. Monoclonal antibodies target these leukemic surface antigens selectively, and minimize off-target toxicity. When added to frontline chemotherapy, rituximab, an antibody directed against CD20, increases cure rates of adults with Burkitt leukemia from 40% to 80%, and those with pre-B ALL from 35% to 50%. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has resulted in marrow CR rates of 55% and a median survival of 6-7 months when given to patients with refractory-relapsed ALL. Blinatumomab, a biallelic T-cell engaging CD3-CD19 monoclonal antibody, also resulted in overall response rates of 40-50% and a median survival of 6.5 months in a similar refractory-relapsed population. Other promising monoclonal antibodies targeting CD20 (ofatumumab, obinutuzumab), or CD19 or CD20 and bound to different cytotoxins or immunotoxins are under development. Combined modalities of chemotherapy and the novel monoclonal antibodies are under investigation.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 24, 11:57 PM

Monoclonal antibodies in acute lymphoblastic leukemia

Elias Jabbour, Susan O'Brien, Farhad Ravandi, HagopKantarjianBlood Jan 2015, DOI: 10.1182/blood-2014-08-596403
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

USP Publishes Monoclonal Antibody Guidelines - Compliance Team Inc

USP Publishes Monoclonal Antibody Guidelines - Compliance Team Inc | Immunology and Biotherapies | Scoop.it
As FDA gears up towards approving biosimilar drugs in the United States, it is unquestionable that the role of biologics has rapidly expanded in healthcare, raising questions and presenting crucial issues associated with their quality and efficacy.
Gilbert Faure au nom de l'ASSIM's insight:

USP standards for mAbs
Currently, licensed monoclonal antibody (mAb) therapeutics include those involved in the activation of effector cells, cell killing, cross-linked induced apoptosis, antagonism against several targets, and agonist antibodies. Because of structural similarities between antibodies of the same class, the United States Pharmacopeial Convention’s (USP) expert panel decided to focus its efforts in developing standards for mAbs on a class of molecules that would be more amenable to a “platform approach” both in terms of manufacturing and analytical development.

USP has been involved in developing quality standards for biologics as part of its expanding portfolio of monographs and general chapters for a long time. In 2012, USP started working on a clearly defined set of quality expectations for recombinant therapeutic mAbs, United States Pharmacopeia (USP) General Chapter <129> “Analytical Procedures for Recombinant Therapeutic Monoclonal Antibodies,” which is set to become official in USP’s compendia of standards, USP 39–National Formulary (NF) 34, on May 1, 2016.

As individual product monographs will possibly describe specific quality attributes of individual drugs, USP deemed it necessary to have a broad foundation of general standards to set minimum quality requirements for molecule classes, and that is what it hopes to achieve with the publication of the new general chapter.

General Chapter <129> provides analytical procedures for murine, chimeric, and humanized IgG isotype mAbs and subtypes (e.g., IgG1 and IgG2). Because subclasses show differences in amino acid sequence and in the number of disulfide bonds, in some cases they require subclass-specific analysis. IgG-type monoclonal antibodies have a molecular weight of approximately 150 kDa. Each molecule consists of two heavy and two light polypeptide chains that have a molecular weight of approximately 50 and 25 kDa, respectively.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Overview | Cancer Immunology & Immunotherapy | Research Solutions | PerkinElmer

Overview | Cancer Immunology & Immunotherapy | Research Solutions | PerkinElmer | Immunology and Biotherapies | Scoop.it
Our Cancer Immunology & Immunotherapy Research Solutions include advanced staining methods, multispectral imaging systems, image analysis services, and contract services.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Safety and activity of the anti-CD79B antibody–...

Safety and activity of the anti-CD79B antibody–... | Immunology and Biotherapies | Scoop.it
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study - The Lanc...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

A novel antibody–drug conjugate targeting SAIL for the treatment of ... - Nature.com

A novel antibody–drug conjugate targeting SAIL for the treatment of ... - Nature.com | Immunology and Biotherapies | Scoop.it
Blood Cancer Journal is a peer-reviewed, open access online journal publishing pre-clinical and clinical work in the field of hematology with ramifications into translational biology research down to new therapies...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Some Side Effect For An Antibody. In the Pipeline:

Some Side Effect For An Antibody. In the Pipeline: | Immunology and Biotherapies | Scoop.it
Some Side Effect For An Antibody http://t.co/mPEOu62QWt
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Identification and Characterization of a Novel IL-4 Receptor α Chain (IL-4Rα) Antagonist to Inhibit IL-4 Signalling - FullText - Cellular Physiology and Biochemistry 2015, Vol. 36, No. 3 - Karger P...

Identification and Characterization of a Novel IL-4 Receptor α Chain (IL-4Rα) Antagonist to Inhibit IL-4 Signalling - FullText - Cellular Physiology and Biochemistry 2015, Vol. 36, No. 3 - Karger P... | Immunology and Biotherapies | Scoop.it
Immunology: Identification and Characterization of a Novel IL-4 Receptor α Chain (IL-4Rα) Antagonist to Inhibit IL... http://t.co/NIyS10pAQg
more...
Krishan Maggon 's curator insight, May 29, 11:17 AM
Cell Physiol Biochem 2015;36:831-842 
(DOI:10.1159/000430259)Fulltext PDF (1 Mb) Table of Contentsnext Article Vol. 36, No. 3, 2015Issue release date: Published online first (Issue-in-Progress)Section title: Original Paper      Identification and Characterization of a Novel IL-4 Receptor α Chain (IL-4Rα) Antagonist to Inhibit IL-4 SignallingAhmed N.a · Dhanapala P.a, b · Suphioglu C.a 
 aNeuroAllergy Research Laboratory (NARL), School of Life and Environmental Sciences, Faculty of Science, Engineering and Built Environment, Deakin University, Geelong, bAustralian Animal Health Laboratory (AAHL), Biosecurity Flagship, Commonwealth Scientific and Industrial Research Organisation (CSIRO), East Geelong, Victoria, Australia
Scooped by Gilbert Faure au nom de l'ASSIM from TAL effector science
Scoop.it!

Multiplexed, targeted gene editing in Nicotiana benthamiana for glyco-engineering and monoclonal antibody production - Li - 2015 - Plant Biotechnology Journal - Wiley Online Library

Multiplexed, targeted gene editing in Nicotiana benthamiana for glyco-engineering and monoclonal antibody production - Li - 2015 - Plant Biotechnology Journal - Wiley Online Library | Immunology and Biotherapies | Scoop.it

(via T. Lahaye, thx)

Li et al, 2015

Biopharmaceutical glycoproteins produced in plants carry N-glycans with plant-specific residues core α(1,3)-fucose and β(1,2)-xylose, which can significantly impact the activity, stability and immunogenicity of biopharmaceuticals. In this study, we have employed sequence-specific transcription activator-like effector nucleases (TALENs) to knock out two α(1,3)-fucosyltransferase (FucT) and the two β(1,2)-xylosyltransferase (XylT) genes within Nicotiana benthamiana to generate plants with improved capacity to produce glycoproteins devoid of plant-specific residues. Among plants regenerated from N. benthamiana protoplasts transformed with TALENs targeting either the FucT or XylT genes, 50% (80 of 160) and 73% (94 of 129) had mutations in at least one FucT or XylT allele, respectively. Among plants regenerated from protoplasts transformed with both TALEN pairs, 17% (18 of 105) had mutations in all four gene targets, and 3% (3 of 105) plants had mutations in all eight alleles comprising both gene families; these mutations were transmitted to the next generation. Endogenous proteins expressed in the complete knockout line had N-glycans that lacked β(1,2)-xylose and had a significant reduction in core α(1,3)-fucose levels (40% of wild type). A similar phenotype was observed in the N-glycans of a recombinant rituximab antibody transiently expressed in the homozygous mutant plants. More importantly, the most desirable glycoform, one lacking both core α(1,3)-fucose and β(1,2)-xylose residues, increased in the antibody from 2% when produced in the wild-type line to 55% in the mutant line. These results demonstrate the power of TALENs for multiplexed gene editing. Furthermore, the mutant N. benthamiana lines provide a valuable platform for producing highly potent biopharmaceutical products.

 


Via dromius
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy | Read by QxMD

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy | Read by QxMD | Immunology and Biotherapies | Scoop.it
Great article: When blood transfusion medicine becomes complicated due to interference by monoclonal a... http://t.co/8LkEpj47Wo #ReadByQxMD
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Frontiers | Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity | NK Cell Biology

Natural killer (NK) cells represent an attractive lymphocyte population for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization and without need for HLA-matc...
Gilbert Faure au nom de l'ASSIM's insight:

.... and without need for human leukocyte antigens-matching. Chimeric antigen receptors (CARs) are able to enhance lymphocyte targeting and activation toward diverse malignancies. CARs consist of an external recognition domain (typically a small chain variable fragment) directed at a specific tumor antigen that is linked with one or more intracellular signaling domains that mediate lymphocyte activation. Most CAR studies have focused on their expression in T cells. However, use of CARs in NK cells is starting to gain traction because they provide a method to redirect these cells more specifically to target refractory cancers. CAR-mediated anti-tumor activity has been demonstrated using NK cell lines, as well as NK cells isolated from peripheral blood, and NK cells produced from human pluripotent stem cells. This review will outline the CAR constructs that have been reported in NK cells with a focus on comparing the use of different signaling domains in combination with other co-activating domains.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from PARP Inhibitors Cancer Review
Scoop.it!

Action and resistance of monoclonal CD20 antibodies therapy in B-cell non-hodgkin lymphomas - Cancer Treatment Reviews

Highlights

 

Anti-CD20 mAbs combined with chemotherapy have become the standard treatment of Non-Hodgkin Lymphomas (NHL).

Mechanisms of action of this anti-CD20 mAbs in vivo are not fully understood.

Binding of rituximab to CD20 is not sufficient to heal every patient with a Non-Hodgkin Lymphoma.

We review the mechanisms of action and resistance of rituximab, and the efforts needed to overcome it.

We also focus on new drugs targeting pathways implicated in resistance to anti-CD20 mAbs.

 

Abstract

Anti-CD20 monoclonal antibodies (mAbs) have improved patient’s survival with non-Hodgkin lymphoma, when combined with chemotherapy. Several mechanisms of action have been reported, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and induction of apoptosis. Despite the large amount of studies and published data, the role each mechanism played in vivo is not fully understood. Furthermore, the reason why a significant percentage of patients are refractory or resistant remains unknown. Several activated intracellular signaling pathways have been implicated in the mechanisms of resistance of rituximab. In the present manuscript, we review those mechanisms and new anti-CD20 mAbs, as well as the efforts being accomplished to overcome it, focusing on new drugs targeting pathways implicated in resistance to rituximab.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 26, 1:53 AM
Cancer Treatment Reviews

Available online 19 May 2015

In Press, Accepted Manuscript — Note to users

 Action and resistance of monoclonal CD20 antibodies therapy in B-cell non-hodgkin lymphomasD. Pérez-Callejo , J. González-Rincón , A. Sánchez , M. Provencio , M. Sánchez-Beato,   doi:10.1016/j.ctrv.2015.05.007
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

New biotechnology for high efficiency purification of live human cells

Cell therapies require a purification step that isolates the desired cell types from contaminating cells.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Visterra collaborates with A*STAR to make monoclonal antibody for dengue | Vaccine News

Visterra Inc., a clinical-stage biotechnology company with a unique technology platform to discover disease targets and create novel treatments for infectious diseases, and the Agency for Science, Technology and Research’s (A*STAR) Drug Discovery...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. - PubMed - NCBI

Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Int J Hematol. 2015 May 21. [Epub ahead of print]
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas, Leukemia & Lymphoma, Informa Healthcare

Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas, Leukemia & Lymphoma, Informa Healthcare | Immunology and Biotherapies | Scoop.it
Phase I Study of the Anti-CD74 Monoclonal Antibody hLL1 in Patients with Previously Treated B-Cell Lymphomas http://t.co/ko87Y6QC2y
more...
Krishan Maggon 's curator insight, May 25, 5:56 AM

No objective response observed in Phase I trial

 

 

Leukemia & Lymphoma

 

ORIGINAL ARTICLE: RESEARCH

Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas

 

Posted online on May 12, 2015. (doi:10.3109/10428194.2015.1028052)




Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Clinical improvement in psoriasis with specific targeting of interleukin-23

Abstract

 

Psoriasis is a chronic inflammatory skin disorder that affects approximately 2–3% of the population worldwide and has severe effects on patients’ physical and psychological well-being1, 2, 3. The discovery that psoriasis is an immune-mediated disease has led to more targeted, effective therapies; recent advances have focused on the interleukin (IL)-12/23p40 subunit shared by IL-12 and IL-23. Evidence suggests that specific inhibition of IL-23 would result in improvement in psoriasis. Here we evaluate tildrakizumab, a monoclonal antibody that targets the IL-23p19 subunit, in a three-part, randomized, placebo-controlled, sequential, rising multiple-dose phase I study in patients with moderate-to-severe psoriasis to provide clinical proof that specific targeting of IL-23p19 results in symptomatic improvement of disease severity in human subjects. A 75% reduction in the psoriasis area and severity index (PASI) score (PASI75) was achieved by all subjects in parts 1 and 3 (pooled) in the 3 and 10 mg kg−1 groups by day 196. In part 2, 10 out of 15 subjects in the 3 mg kg−1 group and 13 out of 14 subjects in the 10 mg kg−1 group achieved a PASI75 by day 112. Tildrakizumab demonstrated important clinical improvement in moderate-to-severe psoriasis patients as demonstrated by improvements in PASI scores and histological samples.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 14, 3:07 AM

NATURE | LETTER

Clinical improvement in psoriasis with specific targeting of interleukin-23Tamara Kopp,Elisabeth Riedl,Christine Bangert,Edward P. Bowman,Elli Greisenegger,Ann Horowitz,Harald Kittler,Wendy M. Blumenschein,Terrill K. McClanahan,Thomas Marbury,Claus Zachariae,Danlin Xu,Xiaoli Shirley Hou,Anish Mehta,Anthe S. Zandvliet,Diana Montgomery,Frank van Aarle& Sauzanne KhaliliehAffiliationsContributionsCorresponding authorNature 521, 222–226 (14 May 2015) doi:10.1038/nature14175Received 23 December 2013 Accepted 23 December 2014 Published online 09 March 2015Corrected online 13 May 2015
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Frontiers | Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies | NK Cell Biology

Natural killer (NK) cells belong to innate immunity and exhibit cytolytic activity against infectious pathogens and tumor cells. NK-cell function is finely tuned by receptors that transduce inhibit...
more...
No comment yet.